Sponsors (2)
The bill speeds and lowers the cost of bringing certain drugs to OTC status—potentially improving patient access—at the expense of increased FDA workload, possible evidence‑quality and safety tradeoffs, and advantages for better‑resourced firms, with the program itself set to expire in 2032.
Patients with chronic conditions (including seniors and uninsured people) may gain earlier access to new nonprescription treatments because the bill creates a pathway aimed at speeding development and review of OTC switches and novel OTC indications.
Drug sponsors (manufacturers) get faster, more interactive FDA review with a designated senior manager and a cross-disciplinary project lead, which can shorten development timelines for eligible applications.
Sponsors and patients could face lower development costs because FDA may accept real‑world evidence and streamlined trial designs, making nonprescription switches more economically attractive.
Patients (especially those with chronic conditions and seniors) could face higher safety or effectiveness risk if reliance on real‑world evidence and streamlined trial designs lowers the evidentiary rigor for OTC approvals.
Hospitals, health systems, and other drug applicants may see delays because prioritizing and facilitating certain applications could increase FDA workload and divert resources from non‑designated reviews.
Smaller drug developers and startups could be disadvantaged because priority designation processes may favor sponsors with resources to apply, concentrating benefits among larger firms and reducing competition.
Based on analysis of 1 section of legislative text.
Creates a voluntary FDA priority designation to speed development and review of eligible nonprescription drugs, requires public condition list and reporting, and sunsets in 2032.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
Introduced July 20, 2026 by Robert E. Latta · Last progress July 20, 2026
Creates a voluntary FDA "priority nonprescription drug" designation to speed development and review of drugs that sponsors seek to switch from prescription to nonprescription use or submit as new nonprescription drugs. The designation requires the FDA to provide expedited review, coordinated senior-level support, frequent developer interactions, and consideration of efficient trial designs while preserving existing approval standards. Requires the FDA to publish a list of conditions that could benefit from nonprescription drugs, accept public comment, and report to Congress on use of the authority; the new authority expires on September 30, 2032.